Iwamoto, Takayuki http://orcid.org/0000-0001-5835-5160
Hara, Fumikata
Uemura, Yukari
Mukai, Hirofumi
Watanabe, Toru
Ohashi, Yasuo
Funding for this research was provided by:
Comprehensive Support Project for Oncology Research
Article History
Received: 4 April 2020
Accepted: 13 May 2020
First Online: 28 May 2020
Compliance with ethical standards
:
: FH received personal fees from Chugai, Kyowa Kirin, Eisai, Pfizer, and Eli Lilly, outside the submitted work. HM received honoraria from AstraZeneca, Pfizer, Takeda, Daiichi Sankyo and Taiho, and research grant from Japanese government, Daiichi Sankyo, Eisai, Nippon Kayaku and Pfizer, outside the submitted work. TW received advisory fee from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD., outside the submitted work. YO received personal fees from Statcom, Daiichi Sankyo, Chugai, Shionogi, Taiho, Sanofi and EP-Crsu and grants from Medical Member System, outside the submitted work. TI and YU declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board at National Hospital Organization Shikoku Cancer Center and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent Informed consent was not required for this retrospective analysis.